The session, scheduled for July 8, 2026, focuses on the strategic deployment of the Northern Ireland-based Health Institution model. Following 2025 regulatory alignment with the MHRA, this framework offers a pathway to circumvent the standard requirement for Performance Study Applications and Competent Authority approvals for specific in-house devices. By utilizing this exemption, sponsors can facilitate in-house assay development and flexible test adaptation, potentially reducing administrative overhead and study start-up times.
Navigating IVDR Article 5(5) for EU and UK Clinical Trial Efficiency
Clinical trial sponsors navigating the complex regulatory landscape between the EU and UK face mounting pressure to accelerate testing timelines. A forthcoming webinar hosted by Xtalks explores how leveraging the Health Institution exemption under IVDR Article 5(5) can bypass traditional bottlenecks and streamline diagnostic sample processing.
Dr. Lindsey Bennie of ARC Regulatory and James Lappin will detail the technical prerequisites for this model, emphasizing the necessity of a robust Quality Management System. Compliance with ISO 13485, ISO 14971, and ISO 15189 standards remains central to ensuring data integrity and patient safety under the IVDR General Safety and Performance Requirements. The presentation aims to provide clinical researchers with a roadmap for integrating these compliant testing strategies into precision medicine programs for European patient cohorts.
Comments (0)
No comments yet. Be the first!